Mounjaro®
Starting from £179.99/mo
Start journey Learn moreYour first Wegovy pen has arrived. You're sitting on the bed holding a small medical device, wondering whether you're doing this right. The injection process itself is straightforward once you understand each step — a once-weekly subcutaneous injection into the abdomen, thigh or upper arm, taking under a minute when you know the routine. These are prescription-only medicines requiring clinical assessment before a prescriber confirms suitability; your Patient Information Leaflet is the definitive guide for your specific pen and dose. What follows is a clear, factual walkthrough of how the process works, based on the NHS's patient guidance on semaglutide.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Wegovy pens are stored in the fridge between 2°C and 8°C. Before you inject, take the pen out and let it sit at room temperature for a short time so the liquid isn't cold against your skin. How long exactly? The Mounjaro and Wegovy Patient Information Leaflets each specify the safe window for their pen, refer to yours rather than any number you read online, because it differs between products and formats.
A common misconception worth clearing up gently: many people assume they need to prime or push a test drop out before injecting, as you might with an insulin pen. Wegovy's pre-filled device works differently, and priming isn't part of the process. Check the specific instructions for your pen rather than borrowing steps from another medicine's routine.
If you're cleaning the injection site, an alcohol swab can be used, let the skin dry fully before injecting, since damp skin can sting. Choose your site: somewhere soft and pinchable, away from the waistband, scars, or anywhere bruised. The upper arm as an injection site is a popular choice once people are more confident, though the abdomen or thigh tend to be easiest to start with.
Hold the pen firmly. Position the cap end flat against your chosen site. Press and hold, the device releases the dose automatically and you'll typically hear or feel a click. Keep the pen pressed to the skin for the duration indicated in your leaflet (usually around ten seconds) so the full dose is delivered before you lift away.
You don't need to pinch the skin hard or insert a needle manually. The auto-injection mechanism handles that. If you want a detailed visual walkthrough tailored to the semaglutide pen, the step-by-step guide to using the Wegovy injection covers this in full.
Once the injection is done, activate the needle shield as the leaflet describes before disposing. Used pens and any spare needles go into a sharps container, never a household bin, your local pharmacy or GP surgery can advise on collection points.
The NHS and Novo Nordisk both emphasise rotation because repeated injections in the same small area can cause localised skin changes, thickening, lumpiness, or reduced absorption. A simple system: move around a clock face on your abdomen, or alternate thighs each week, or cycle through all three approved sites in sequence. Write it on your phone's calendar if that helps you track it. The practical guide to Wegovy injections has more on site-selection.
Mild redness or a small raised patch at the injection site is normal and usually fades within hours. Widespread skin reactions, swelling of the face or throat, or difficulty breathing need urgent medical attention. The most common effects people notice in the days after injecting are gastrointestinal: nausea, loose stools, or reduced appetite, these tend to be most pronounced after starting or stepping up the dose, and ease for most people within a couple of weeks. NHS England's guidance on weight-management injections has a clear summary of what to expect and when to seek help.
The injection process is the same physical routine at every dose level; what changes is the strength in the pen. Wegovy titrates upward over several months (from 0.25 mg through to the maintenance dose) and your prescriber decides the timing of each step based on how you're tolerating treatment. You can read more about how the Wegovy injection fits into the broader treatment picture, including the licensed dose schedule.
If you miss a dose and your next scheduled day is still more than two days away, it's generally possible to inject the missed one; if it's closer than that, skip it and carry on from the next planned date. The Patient Information Leaflet spells this out clearly, and any questions about your specific situation are best put to a prescriber rather than answered by general guidance.
For a broader look at how semaglutide compares with other licensed weight-loss treatments, or if you're still deciding whether Wegovy is the right route for you, our page on weight loss injections including Ozempic may help you compare your options before speaking to a prescriber. If you'd like to check your eligibility with a clinician, a free consultation with our GPhC-registered prescribers takes a few minutes and is reviewed the same day.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.